Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

11/03/2015 Sustainability: the Barcelona Synchrotron Park focuses on birds and bats… 05/03/2015 Wastewater that produces green energy 26/02/2015 ALBA, CSIC and Alibava develop an X-Ray detector 20/02/2015 The pressure that makes conductivity higher: new record in the ICN2 11/02/2015 Presentation of the Big Data CoE Barcelona initiative 06/02/2015 Come investigate at the ALBA synchrotron: 2015 new call for proposals
34 35 36 37 38 39 40 41 42 43 44